{"doi":"10.3390/cells13121023","title":"Recent Advances in Molecular and Genetic Research on Uveal Melanoma","abstract":"<jats:p>Uveal melanoma (UM), a distinct subtype of melanoma, presents unique challenges in its clinical management due to its complex molecular landscape and tendency for liver metastasis. This review highlights recent advancements in understanding the molecular pathogenesis, genetic alterations, and immune microenvironment of UM, with a focus on pivotal genes, such as GNAQ/11, BAP1, and CYSLTR2, and delves into the distinctive genetic and chromosomal classifications of UM, emphasizing the role of mutations and chromosomal rearrangements in disease progression and metastatic risk. Novel diagnostic biomarkers, including circulating tumor cells, DNA and extracellular vesicles, are discussed, offering potential non-invasive approaches for early detection and monitoring. It also explores emerging prognostic markers and their implications for patient stratification and personalized treatment strategies. Therapeutic approaches, including histone deacetylase inhibitors, MAPK pathway inhibitors, and emerging trends and concepts like CAR T-cell therapy, are evaluated for their efficacy in UM treatment. This review identifies challenges in UM research, such as the limited treatment options for metastatic UM and the need for improved prognostic tools, and suggests future directions, including the discovery of novel therapeutic targets, immunotherapeutic strategies, and advanced drug delivery systems. The review concludes by emphasizing the importance of continued research and innovation in addressing the unique challenges of UM to improve patient outcomes and develop more effective treatment strategies.</jats:p>","journal":"Cells","year":2024,"id":644392,"datarank":0.6326174154993197,"base_score":3.295836866004329,"endowment":3.295836866004329,"self_citation_contribution":0.4943755299006494,"citation_network_contribution":0.1382418855986703,"self_endowment_contribution":0.4943755299006494,"citer_contribution":0.1382418855986703,"corpus_percentile":null,"corpus_rank":null,"citation_count":26,"citer_count":23,"citers_with_citation_signal":10,"citers_with_endowment":10,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":165717,"name":"Andrew Mitchell","orcid":null,"position":1,"is_corresponding":false},{"id":1677252,"name":"Sylvain L. Guérin","orcid":"0000-0002-6767-5833","position":2,"is_corresponding":false},{"id":1110504,"name":"Solange Landreville","orcid":"0000-0002-9164-0657","position":3,"is_corresponding":false},{"id":1677250,"name":"Aurélie Fuentes-Rodriguez","orcid":"0000-0002-6956-6024","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Recent Advances in Molecular and Genetic Research on Uveal Melanoma","abstract":"<jats:p>Uveal melanoma (UM), a distinct subtype of melanoma, presents unique challenges in its clinical management due to its complex molecular landscape and tendency for liver metastasis. This review highlights recent advancements in understanding the molecular pathogenesis, genetic alterations, and immune microenvironment of UM, with a focus on pivotal genes, such as GNAQ/11, BAP1, and CYSLTR2, and delves into the distinctive genetic and chromosomal classifications of UM, emphasizing the role of mutations and chromosomal rearrangements in disease progression and metastatic risk. Novel diagnostic biomarkers, including circulating tumor cells, DNA and extracellular vesicles, are discussed, offering potential non-invasive approaches for early detection and monitoring. It also explores emerging prognostic markers and their implications for patient stratification and personalized treatment strategies. Therapeutic approaches, including histone deacetylase inhibitors, MAPK pathway inhibitors, and emerging trends and concepts like CAR T-cell therapy, are evaluated for their efficacy in UM treatment. This review identifies challenges in UM research, such as the limited treatment options for metastatic UM and the need for improved prognostic tools, and suggests future directions, including the discovery of novel therapeutic targets, immunotherapeutic strategies, and advanced drug delivery systems. The review concludes by emphasizing the importance of continued research and innovation in addressing the unique challenges of UM to improve patient outcomes and develop more effective treatment strategies.</jats:p>","is_dataset_classified":null,"base_score":3.258096538021482,"endowment":3.258096538021482,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38920653","pmcid":"PMC11201764","openalex_id":"https://openalex.org/W4399573418","authors":[],"funders":[{"funder_name":"Eye Disease Foundation","grant_id":"85577","title":null},{"funder_name":"Fonds de Recherche du Québec - Santé","grant_id":"85578","title":null},{"funder_name":"Fondation du CHU de Québec-Desjardins","grant_id":"","title":null},{"funder_name":"Fonds de soutien à la recherche Joseph-Demers of Université Laval","grant_id":"","title":null},{"funder_name":"Fondation du CHU de Québec","grant_id":"","title":null},{"funder_name":"Vision Health Research Network","grant_id":"","title":null},{"funder_name":"Eye Disease Foundation","grant_id":"","title":null},{"funder_name":"Québec Cell, Tissue and Gene Therapy Network–ThéCell","grant_id":"","title":null},{"funder_name":"Centre de recherche sur le cancer de l’Université Laval","grant_id":"","title":null}],"total_grants":9,"fwci":10.1559,"citation_percentile":0.98905071,"influential_citations":0,"citation_trend":[{"year":2024,"count":1},{"year":2025,"count":15},{"year":2026,"count":9}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2073-4409/13/12/1023/pdf?version=1718192207","host_type":"journal"},{"url":"https://www.mdpi.com/2073-4409/13/12/1023/pdf?version=1718192207","host_type":"publisher"},{"url":"https://www.mdpi.com/2073-4409/13/12/1023/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/cells13121023","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38920653","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11201764","host_type":"repository"},{"url":"https://doaj.org/article/8bad78abdc8c4dc8ab3bfa9cd669f5a5","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11201764/pdf/cells-13-01023.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11201764","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11201764?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Ocular Oncology and Treatments","Retinal Development and Disorders","Immunotherapy and Immune Responses","Humans","Uveal Neoplasms","Melanoma","Biomarkers, Tumor","Tumor Microenvironment","Mutation","Uveal Melanoma"],"mesh_terms":["Uveal Melanoma","Humans","Melanoma","Mutation","Biomarkers, Tumor","Uveal Neoplasms","Tumor Microenvironment"],"keywords":["Melanoma","Computational biology","Biology","Medicine","Cancer research","Molecular mechanisms","Challenges","Uveal Melanoma","Novel Biomarkers","Emerging Therapeutics","Liquid Biopsies"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Industry, innovation and infrastructure"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"refsnp"},{"name":"eudract"},{"name":"nct"},{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T01:03:31.885603Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}